Sanjivani Paranteral Ltd
Incorporated in 1994, Sanjivani Parenteral Ltd is a research-based and export-oriented pharmaceutical company[1]
- Market Cap ₹ 167 Cr.
- Current Price ₹ 136
- High / Low ₹ 269 / 128
- Stock P/E 24.2
- Book Value ₹ 36.5
- Dividend Yield 0.37 %
- ROCE 22.4 %
- ROE 18.2 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 25.4%
Cons
- Promoter holding is low: 31.3%
- Debtor days have increased from 70.8 to 94.0 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 133.03 | 115.31 | 32.53 | 17.96 | 25.09 | 16.29 | 25.09 | 30.59 | 41.45 | 54.41 | 70.10 | 64.76 | |
| 127.71 | 120.84 | 55.81 | 70.17 | 26.85 | 16.62 | 22.95 | 24.86 | 35.80 | 46.18 | 59.74 | 55.36 | |
| Operating Profit | 5.32 | -5.53 | -23.28 | -52.21 | -1.76 | -0.33 | 2.14 | 5.73 | 5.65 | 8.23 | 10.36 | 9.40 |
| OPM % | 4.00% | -4.80% | -71.56% | -290.70% | -7.01% | -2.03% | 8.53% | 18.73% | 13.63% | 15.13% | 14.78% | 14.52% |
| 1.24 | 0.73 | 2.85 | 0.48 | 0.96 | 0.25 | 0.26 | 0.24 | 0.54 | 0.52 | 1.21 | 1.24 | |
| Interest | 7.92 | 8.81 | 4.79 | 0.45 | 0.33 | 0.66 | 0.13 | 0.21 | 0.36 | 0.25 | 0.59 | 0.54 |
| Depreciation | 1.41 | 1.36 | 1.20 | 1.19 | 1.17 | 1.07 | 0.86 | 0.88 | 0.89 | 0.93 | 0.62 | 0.86 |
| Profit before tax | -2.77 | -14.97 | -26.42 | -53.37 | -2.30 | -1.81 | 1.41 | 4.88 | 4.94 | 7.57 | 10.36 | 9.24 |
| Tax % | -13.00% | -2.20% | -0.72% | -0.60% | -10.00% | -5.52% | -0.71% | 0.61% | 8.70% | 18.63% | 21.81% | 25.00% |
| -2.41 | -14.64 | -26.22 | -53.06 | -2.07 | -1.71 | 1.42 | 4.85 | 4.51 | 6.17 | 8.10 | 6.92 | |
| EPS in Rs | -4.09 | -24.82 | -44.45 | -89.96 | -3.51 | -2.90 | 1.67 | 4.85 | 4.51 | 5.28 | 6.82 | 5.63 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 7.33% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | 21% |
| 3 Years: | 16% |
| TTM: | -8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 37% |
| 3 Years: | 15% |
| TTM: | -15% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 65% |
| 3 Years: | 36% |
| 1 Year: | -42% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 25% |
| Last Year: | 18% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.90 | 5.90 | 5.90 | 5.90 | 5.90 | 5.90 | 8.50 | 10.00 | 10.00 | 11.68 | 11.88 | 12.28 |
| Reserves | 26.24 | 11.60 | -14.62 | -58.72 | -53.10 | -54.81 | -53.39 | -17.58 | -13.07 | 16.22 | 26.12 | 32.55 |
| 57.06 | 62.20 | 59.89 | 48.23 | 48.09 | 48.91 | 46.05 | 6.00 | 2.49 | 0.97 | 5.62 | 6.70 | |
| 24.48 | 13.42 | 9.15 | 29.61 | 17.09 | 15.66 | 18.11 | 19.87 | 21.59 | 14.53 | 21.37 | 6.85 | |
| Total Liabilities | 113.68 | 93.12 | 60.32 | 25.02 | 17.98 | 15.66 | 19.27 | 18.29 | 21.01 | 43.40 | 64.99 | 58.38 |
| 13.52 | 12.69 | 11.19 | 10.17 | 8.99 | 8.04 | 7.62 | 7.42 | 7.57 | 9.94 | 20.56 | 21.28 | |
| CWIP | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.00 | 3.00 | 3.91 |
| 100.10 | 80.38 | 49.08 | 14.80 | 8.94 | 7.57 | 11.60 | 10.82 | 13.39 | 33.46 | 41.43 | 33.19 | |
| Total Assets | 113.68 | 93.12 | 60.32 | 25.02 | 17.98 | 15.66 | 19.27 | 18.29 | 21.01 | 43.40 | 64.99 | 58.38 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.20 | 0.45 | 9.57 | 3.05 | 2.48 | -0.17 | 0.58 | 8.52 | 4.68 | -10.70 | -0.24 | -1.55 | |
| 8.68 | -0.50 | 0.30 | -0.20 | 0.02 | -0.12 | -0.42 | -0.67 | -0.99 | -12.21 | -5.81 | -4.47 | |
| -7.30 | -0.51 | -10.05 | -2.83 | -2.30 | 0.33 | -0.26 | -7.68 | -3.73 | 23.16 | 6.14 | 6.54 | |
| Net Cash Flow | 0.18 | -0.57 | -0.18 | 0.03 | 0.20 | 0.03 | -0.09 | 0.17 | -0.04 | 0.24 | 0.09 | 0.52 |
| Free Cash Flow | 7.47 | -0.06 | 9.87 | 2.85 | 2.50 | -0.30 | 0.15 | 7.84 | 3.63 | -14.00 | -11.48 | -5.21 |
| CFO/OP | -23% | -8% | -41% | -6% | -143% | 48% | 28% | 150% | 84% | -117% | 10% | 6% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 184.24 | 151.59 | 358.38 | 107.71 | 75.79 | 23.97 | 96.45 | 58.71 | 17.52 | 31.53 | 86.85 | |
| Inventory Days | 68.59 | 65.35 | 127.41 | 34.08 | 13.56 | 66.80 | 22.43 | 51.89 | 105.21 | 124.70 | 93.96 | |
| Days Payable | 37.50 | 19.51 | 42.51 | 169.13 | 292.82 | 434.62 | 261.00 | 339.20 | 269.82 | 73.56 | 137.51 | |
| Cash Conversion Cycle | 215.34 | 197.43 | 443.28 | -27.33 | -203.47 | -343.84 | -142.12 | -228.61 | -147.08 | 82.67 | 43.30 | |
| Working Capital Days | 61.38 | 26.72 | -196.58 | -1,285.22 | -714.43 | -1,162.44 | -707.31 | -173.01 | -129.27 | 35.55 | 83.73 | |
| ROCE % | 5.95% | -7.31% | -35.52% | -227.18% | -258.43% | 265.52% | 55.28% | 30.21% |
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Inventory Levels INR Crores |
|
|||||||
| Export Revenue Mix % |
||||||||
| Number of Countries in Reach number |
||||||||
| Product Portfolio Size number |
||||||||
| Annual Ampoules Capacity million |
||||||||
| Annual B Lactam Tablet Capacity million |
||||||||
| Annual Liquid Injectables Capacity million |
||||||||
| Annual Tablet Capacity (General) million |
||||||||
| Annual Vial Capacity million |
||||||||
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 11h
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
17h - Audio recording of 15 May 2026 earnings call for Q4 and FY2026 uploaded.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1d - FY26 audited results: revenue ₹697.56 mn, EBITDA ₹114 mn, PAT ₹66.94 mn; Pune IV fluid plant commissioned.
-
Board Meeting Intimation for Intimation Of Notice Of Board Meeting To Be Held On Thursday, 21St May, 2026 Pursuant To Regulation 29 Of SEBI (LODR) Regulations, 2015.
1d - Board meeting on 21 May 2026 to consider fund raising via equity, warrants, QIP or private placement.
- Announcement under Regulation 30 (LODR)-Investor Presentation 2d
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
May 2026TranscriptAI SummaryPPT
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Aug 2024TranscriptAI SummaryPPT
-
Jul 2024TranscriptAI SummaryPPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023TranscriptAI SummaryPPT
-
Nov 2023Transcript PPT
-
Oct 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Mar 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
Business Overview:[1][2]
SPL is a WHO-GMP, DIGEMID, and
DDA-certified pharmaceutical company specializing in high-quality parenteral and
oral solid formulations. It serves key therapeutic areas including CNS, CVS, antibiotics, urology, anesthetics, gastro enterology, anti-diabetics, anti-fungals, anti-depressants, anti-allergics, muscle relaxants, and vitamin supplements.